VERA · Vera Therapeutics, Inc.
AI read · Good for VERA
The AI's read
That view supports a positive reading of Vera's prospects. The story gives no new trial findings or company results, so the support comes from JPMorgan's opinion alone.
JPMorgan says to keep buying Vera Therapeutics, setting a price target of $75.
Good for VERA
JPMorgan's rating and $75 target show a positive view of Vera. The story gives no new trial findings or company results, so the support comes only from the analyst's opinion.
Get alerts for VERA
Follow Vera Therapeutics, Inc. (VERA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VERAFree on the App Store and Google Play, or on the web.